{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T13:56:04Z","timestamp":1788270964277,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T00:00:00Z","timestamp":1394668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ijchv-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vessels"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ijchv.2014.03.005","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T19:44:31Z","timestamp":1395431071000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives"],"prefix":"10.1016","volume":"3","author":[{"given":"Enrico","family":"Vizzardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Regazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Caretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Gavazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Sciatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivano","family":"Bonadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Trichaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Raddino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijchv.2014.03.005_bb0005","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMra000050","article-title":"Aldosterone in congestive heart failure","volume":"345","author":"Weber","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0010","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","article-title":"Eplerenone: cardiovascular protection","volume":"107","author":"Brown","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ejheart.2004.04.013","article-title":"The clinical implications of aldosterone escape in congestive heart failure","volume":"6","author":"Struthers","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0020","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/CIRCULATIONAHA.109.915215","article-title":"Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via \u201cnongenomic effects\u201d","volume":"122","author":"Mohammed","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/jmcc.1994.1098","article-title":"Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone","volume":"26","author":"Brilla","year":"1994","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/1568016043356219","article-title":"Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure","volume":"2","author":"Fraccarollo","year":"2004","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s000590050024","article-title":"Aldosterone and myocardial fibrosis in heart failure","volume":"25","author":"Brilla","year":"2000","journal-title":"Herz"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0040","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","article-title":"Induction of cardiac fibrosis by aldosterone","volume":"32","author":"Lijnen","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0045","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/HYPERTENSIONAHA.109.135392","article-title":"Critical role of apoptosis signal-regulating kinase 1 in aldosterone\/salt-induced cardiac inflammation and fibrosis","volume":"54","author":"Nakamura","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0050","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nrd2685","article-title":"Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection","volume":"7","author":"Perico","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0055","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/j.jacc.2006.07.049","article-title":"Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy","volume":"48","author":"Assomull","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2010.06.062","article-title":"Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death","volume":"57","author":"Iles","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1152\/physrev.1999.79.1.215","article-title":"Molecular mechanisms of myocardial remodeling","volume":"79","author":"Swynghedauw","year":"1999","journal-title":"Physiol Rev"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0070","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.108.805804","article-title":"Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins","volume":"119","author":"G\u00f3mez","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0075","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/ATVBAHA.110.208462","article-title":"Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality","volume":"30","author":"Velagaleti","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0080","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.4065\/80.12.1623","article-title":"Aldosterone receptor antagonists in the medical management of chronic heart failure","volume":"80","author":"Tang","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0008-6363(03)00251-7","article-title":"Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure","volume":"58","author":"Cittadini","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0090","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0008-6363(03)00333-X","article-title":"Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction","volume":"58","author":"Schafer","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0095","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction","volume":"141","author":"Modena","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0115","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0120","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1254\/jphs.10285FP","article-title":"SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity","volume":"115","author":"Nariai","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0125","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14728214.2011.618495","article-title":"Emerging drugs which target the renin\u2013angiotensin\u2013aldosterone system","volume":"16","author":"Steckelings","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0130","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrcardio.2010.85","article-title":"Novel therapeutic targets for hypertension","volume":"7","author":"Paulis","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0135","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0140","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0145","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0150","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10741-005-2344-2","article-title":"Mineralocorticoid receptors: distribution and activation","volume":"10","author":"Funder","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0160","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0165","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCHEARTFAILURE.113.000530","article-title":"Race influences the safety and efficacy of spironolactone in severe heart failure","volume":"6","author":"Vardeny","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0170","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0175","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"Hayashi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0180","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/eurheartj\/ehn383","article-title":"Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction","volume":"29","author":"Palmer","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0185","doi-asserted-by":"crossref","first-page":"H647","DOI":"10.1152\/ajpheart.2001.281.2.H647","article-title":"Effect of a selective aldosterone receptor antagonist in myocardial infarction","volume":"281","author":"Delyani","year":"2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0190","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jacc.2003.10.058","article-title":"Acute aldosterone antagonism improves cardiac vagal control in humans","volume":"43","author":"Fletcher","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0195","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.112.110536","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations","volume":"126","author":"Rogers","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0200","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/CIRCHEARTFAILURE.112.000173","article-title":"Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study","volume":"6","author":"Krum","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0205","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/eurheartj\/eht247","article-title":"The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial","volume":"34","author":"Collier","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0210","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Writing Committee Members","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0215","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"McMurray","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0220","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","article-title":"ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation","volume":"33","author":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0225","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","article-title":"Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure","volume":"106","author":"Vizzardi","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0230","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","article-title":"Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction","volume":"3","author":"Udelson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0235","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","article-title":"Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure","volume":"50","author":"Chan","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ijchv.2014.03.005_bb0240","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","article-title":"Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms","volume":"347","author":"Vizzardi","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0245","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","author":"Meta-analysis Global Group in Chronic Heart F","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0250","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0255","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.cardfail.2009.03.006","article-title":"Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction","volume":"15","author":"Desai","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0260","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.0000138680.89536.A9","article-title":"Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure","volume":"110","author":"Mottram","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0265","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","article-title":"Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0270","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","article-title":"Aldosterone antagonist improves diastolic function in essential hypertension","volume":"40","author":"Grandi","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0275","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0280","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","article-title":"Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"6","author":"Shah","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0285","series-title":"Aldo-antagonist falls short but impresses in preserved-EF heart failure: TOPCAT","year":"2013"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0290","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0735-1097(00)01129-3","article-title":"Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats","volume":"37","author":"Lacolley","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0295","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","article-title":"Reactive and reparative myocardial fibrosis in arterial hypertension in the rat","volume":"26","author":"Brilla","year":"1992","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0300","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/01.CIR.81.4.1161","article-title":"Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications","volume":"81","author":"Pfeffer","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0305","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1161\/CIRCULATIONAHA.108.817411","article-title":"Relations of biomarkers representing distinct biological pathways to left ventricular geometry","volume":"118","author":"Velagaleti","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0310","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1161\/CIRCULATIONAHA.111.067918","article-title":"Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling","volume":"124","author":"Leopold","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0315","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1161\/hy1101.098549","article-title":"Biochemical assessment of myocardial fibrosis in hypertensive heart disease","volume":"38","author":"Lopez","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0320","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0325","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2009.08.021","article-title":"Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone","volume":"54","author":"Mak","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0330","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","article-title":"Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease","volume":"106","author":"Edwards","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0335","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1161\/CIRCULATIONAHA.105.571653","article-title":"Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study","volume":"112","author":"Izawa","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0340","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/heartjnl-2012-303329","article-title":"Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade","volume":"99","author":"Kosmala","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0345","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.HYP.37.5.1236","article-title":"Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients","volume":"37","author":"Laurent","year":"2001","journal-title":"Hypertension"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0350","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.STR.0000065428.03209.64","article-title":"Aortic stiffness is an independent predictor of fatal stroke in essential hypertension","volume":"34","author":"Laurent","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1751-7133.2008.07210.x","article-title":"Arterial stiffness and vascular load in heart failure","volume":"14","author":"Ooi","year":"2008","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0360","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/ejechocard\/jen304","article-title":"Proximal aortic stiffness is related to left ventricular function and exercise capacity in patients with dilated cardiomyopathy","volume":"10","author":"Patrianakos","year":"2009","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0365","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/01.CIR.0000051458.39176.43","article-title":"Aortic distensibility independently affects exercise tolerance in patients with dilated cardiomyopathy","volume":"107","author":"Bonapace","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0370","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1161\/01.ATV.0000160548.78317.29","article-title":"Mechanisms, pathophysiology, and therapy of arterial stiffness","volume":"25","author":"Zieman","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0375","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0380","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.yjmcc.2005.05.015","article-title":"Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure","volume":"39","author":"Nehme","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0385","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/HJH.0b013e3280f31b6e","article-title":"The influence of serum aldosterone and the aldosterone\u2013renin ratio on pulse wave velocity in hypertensive patients","volume":"25","author":"Park","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0390","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1734-1140(11)70613-2","article-title":"Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness","volume":"63","author":"Baldo","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0395","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1532-5415.2010.02905.x","article-title":"Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension","volume":"58","author":"Kithas","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0400","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0405","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0410","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0415","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCHEARTFAILURE.112.000003","article-title":"Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials","volume":"6","author":"Bapoje","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0420","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1161\/01.CIR.0000138973.55605.38","article-title":"Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction","volume":"110","author":"Perrier","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0425","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(60)91487-2","article-title":"The influence of aldosterone on magnesium metabolism","volume":"2","author":"Hanna","year":"1960","journal-title":"Lancet"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0430","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J Card Fail"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0435","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/978-1-4899-5561-6_23","article-title":"The effect of potassium canrenoate (aldactone) on the norepinephrine metabolism and potassium ionic currents of the heart","volume":"3","author":"Antaloczy","year":"1982","journal-title":"Adv Myocardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0440","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0735-1097(02)02855-3","article-title":"Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy","volume":"41","author":"Kasama","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0445","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/eurheartj\/ehi478","article-title":"Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction","volume":"26","author":"Milliez","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0450","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1540-8167.2006.00372.x","article-title":"Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure","volume":"17","author":"Shroff","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0455","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","article-title":"Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis","volume":"45","author":"Healey","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0460","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","article-title":"Prevention of atrial fibrillation by renin\u2013angiotensin system inhibition a meta-analysis","volume":"55","author":"Schneider","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0465","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0470","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1161\/CIRCULATIONAHA.106.670109","article-title":"Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death","volume":"115","author":"Pitt","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0475","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0480","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0735-1097(01)01116-0","article-title":"Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure","volume":"37","author":"Tsutamoto","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0485","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0490","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1536\/jhj.44.681","article-title":"Effects of spironolactone and metoprolol on QT dispersion in heart failure","volume":"44","author":"Akbulut","year":"2003","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0495","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/BF02877769","article-title":"Probrain natriuretic peptide for assessment of efficacy in heart failure treatment","volume":"24","author":"Ozkara","year":"2007","journal-title":"Adv Ther"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0500","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.2967\/jnumed.107.045427","article-title":"Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure","volume":"48","author":"Kasama","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0505","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.ijchv.2014.03.005_bb0510","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jjcc.2010.11.006","article-title":"Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure","volume":"57","author":"Kimura","year":"2011","journal-title":"J Cardiol"}],"container-title":["IJC Heart & Vessels"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214763214000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214763214000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T19:51:00Z","timestamp":1565293860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214763214000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":102,"alternative-id":["S2214763214000157"],"URL":"https:\/\/doi.org\/10.1016\/j.ijchv.2014.03.005","relation":{},"ISSN":["2214-7632"],"issn-type":[{"value":"2214-7632","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vessels","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijchv.2014.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}